Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jan 8;4(1):e003536.
doi: 10.1136/bmjopen-2013-003536.

Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial

Sergio Livigni  1 , Guido Bertolini, Carlotta Rossi, Fiorenza Ferrari, Michele Giardino, Marco Pozzato, Giuseppe Remuzzi; GiViTI: Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva (Italian Group for the Evaluation of Interventions in Intensive Care Medicine) is an independent collaboration network of Italian Intensive Care units
Collaborators, Affiliations
Randomized Controlled Trial

Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial

Sergio Livigni et al. BMJ Open. .

Abstract

Objectives: Coupled plasma filtration adsorption (CPFA, Bellco, Italy), to remove inflammatory mediators from blood, has been proposed as a novel treatment for septic shock. This multicenter, randomised, non-blinded trial compared CPFA with standard care in the treatment of critically ill patients with septic shock.

Design: Prospective, multicenter, randomised, open-label, two parallel group and superiority clinical trial.

Setting: 18 Italian adult, general, intensive care units (ICUs).

Participants: Of the planned 330 adult patients with septic shock, 192 were randomised to either have CPFA added to the standard care, or not. The external monitoring committee excluded eight ineligible patients who were erroneously included.

Interventions: CPFA was to be performed daily for 5 days, lasting at least 10 h/day.

Primary and secondary outcome measures: The primary endpoint was mortality at discharge from the hospital at which the patient last stayed. Secondary endpoints were: 90-day mortality, new organ failures and ICU-free days within 30 days.

Results: There was no statistical difference in hospital mortality (47.3% controls, 45.1% CPFA; p=0.76), nor in secondary endpoints, namely the occurrence of new organ failures (55.9% vs 56.0%; p=0.99) or free-ICU days during the first 30 days (6.8 vs 7.5; p=0.35). The study was terminated on the grounds of futility. Several patients randomised to CPFA were subsequently found to be undertreated. An a priori planned subgroup analysis showed those receiving a CPFA dose >0.18 L/kg/day had a lower mortality compared with controls (OR 0.36, 95% CI 0.13 to 0.99).

Conclusions: CPFA did not reduce mortality in patients with septic shock, nor did it positively affect other important clinical outcomes. A subgroup analysis suggested that CPFA could reduce mortality, when a high volume of plasma is treated. Owing to the inherent potential biases of such a subgroup analysis, this result can only be viewed as a hypothesis generator and should be confirmed in future studies.

Clinicaltrialsgov: NCT00332371; ISRCTN24534559.

Keywords: INFECTIOUS DISEASES.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Coupled plasma filtration adsorption schema.
Figure 2
Figure 2
Flow chart of participants.
Figure 3
Figure 3
Survival curves.
Figure 4
Figure 4
Hospital mortality according to the quantity of volume of plasma treated (whiskers represent 95% CI).
See this image and copyright information in PMC

References

    1. Feezor RJ, Oberholzer C, Baker HV, et al. Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria. Infect Immun 2003;71:5803–13 - PMC - PubMed
    1. Bozza FA, Salluh JI, Japiassu AM, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007;11:R49. - PMC - PubMed
    1. Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007;167:1655–63 - PMC - PubMed
    1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;369:840–51 - PubMed
    1. Bochud PY, Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 2003;326:262–6 - PMC - PubMed

Publication types

Associated data